Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma.
Wang Y, Zhou W, Chen J, Chen J, Deng P, Chen H, Sun Y, Yu Z, Pang D, Liu L, Wang P, Hong JH, Teh BT, Huang H, Li W, Yi Z, Lim ST, Chen Y, Ong CK, Liu M, Tan J.
Wang Y, et al. Among authors: wang p.
MedComm (2020). 2023 Jun 16;4(4):e284. doi: 10.1002/mco2.284. eCollection 2023 Aug.
MedComm (2020). 2023.
PMID: 37334274
Free PMC article.